Table 1 |
||||||||||||
|
Predicted protein coding somatic changes within the initial and the drug resistant recurrent tumor |
||||||||||||
|
Tumor |
Chr. |
Ensembl gene ID |
Ensembl display |
HUGO ID |
Chr. position |
Ref. |
Obs. |
Het. |
Protein position |
Ref. amino acid |
Alt. amino acid |
Description |
|
|
||||||||||||
|
Initial |
6 |
ENSG00000197062 |
ZNF187-201 |
12978 |
28352058 |
G |
T |
K |
62 |
G |
C |
Zinc finger protein 187 (Zinc finger and SCAN domain-containing protein 26) (Protein SRE-ZBP) |
|
Initial |
8 |
ENSG00000169946 |
ZFPM2-202 |
16700 |
106884238 |
A |
G |
R |
785 |
K |
E |
Zinc finger protein ZFPM2 (Zinc finger protein multitype 2) (Friend of GATA protein 2) (FOG-2) (hFOG-2) |
|
Initial |
13 |
ENSG00000139687 |
RB1-002 |
9884 |
47832247 |
T |
A |
W |
234 |
L |
* |
Retinoblastoma-associated protein (pRb) (Rb) (pp110) (p105-Rb) |
|
Initial |
17 |
ENSG00000141510 |
TP53-202 |
11998 |
7518231 |
C |
A |
M |
259 |
D |
Y |
Cellular tumor antigen p53 (Tumor suppressor p53) (Phosphoprotein p53) (Antigen NY-CO-13) |
|
Recurrence |
1 |
ENSG00000146463 |
ZMYM4-001 |
13055 |
35608585 |
G |
C |
S |
317 |
Q |
H |
Zinc finger MYM-type protein 4 (Zinc finger protein 262) |
|
Recurrence |
2 |
ENSG00000118997 |
DNAH7-201 |
18661 |
196431742 |
C |
G |
S |
2590 |
V |
L |
Dynein heavy chain 7, axonemal (Axonemal beta dynein heavy chain 7) (Ciliary dynein heavy chain 7) (Dynein heavy chain-like protein 2) (HDHC2) |
|
Recurrence |
4 |
ENSG00000156234 |
CXCL13-001 |
10639 |
78747983 |
G |
A |
R |
56 |
R |
H |
C-X-C motif chemokine 13 Precursor (Small-inducible cytokine B13) (B lymphocyte chemoattractant) (CXC chemokine BLC) (B cell-attracting chemokine 1) (BCA-1) (ANGIE) |
|
Recurrence |
6 |
ENSG00000204228 |
HSD17B8-001 |
3554 |
33281235 |
G |
A |
R |
141 |
A |
T |
Estradiol 17-beta-dehydrogenase 8 (EC 1.1.1.62) (Testosterone 17-beta-dehydrogenase 8) (EC 1.1.1.63) (17-beta-hydroxysteroid dehydrogenase 8) (17-beta-HSD 8) (Protein Ke6) (Ke-6) |
|
Recurrence |
7 |
ENSG00000186472 |
PCLO-201 |
13406 |
82419723 |
T |
C |
Y |
2759 |
T |
A |
Protein piccolo (Aczonin) |
|
Recurrence |
11 |
ENSG00000152578 |
GRIA4-201 |
4574 |
105355581 |
C |
T |
Y |
872 |
R |
C |
Glutamate receptor 4 Precursor (GluR-4) (GluR4) (GluR-D) (Glutamate receptor ionotropic, AMPA 4) (AMPA-selective glutamate receptor 4) |
|
Recurrence |
14 |
ENSG00000165762 |
OR4K2-201 |
14728 |
19414855 |
C |
T |
Y |
197 |
L |
F |
Olfactory receptor 4K2 (Olfactory receptor OR14-15) |
|
Recurrence |
14 |
ENSG00000054654 |
SYNE2-206 |
17084 |
63500386 |
C |
G |
S |
302 |
A |
G |
Nesprin-2 (Nuclear envelope spectrin repeat protein 2) (Synaptic nuclear envelope protein 2) (Syne-2) (Nucleus and actin connecting element protein) (Protein NUANCE) |
|
Recurrence |
18 |
ENSG00000173482 |
PTPRM-202 |
9675 |
8333477 |
G |
A |
R |
929 |
A |
T |
Receptor-type tyrosine-protein phosphatase mu Precursor (Protein-tyrosine phosphatase mu) (R-PTP-mu) (EC 3.1.3.48) |
|
|
||||||||||||
|
Validated non-synonymous single nucleotide variations (SNVs) predicted by high-throughput sequencing are listed with the corresponding chromosome (CHr.), Ensembl gene ID, the HUGO ID, chromosomal position, the identity of the base at this location in the reference genome (Ref.), the observed base that does not match the reference (Obs.), and the IUPAC code at the heterogeneous position (Het.), the position in the protein where the amino acid changed as a result of the SNV, the reference amino acid, the altered amino acid, and the Ensembl description for this gene. Those marked as 'Initial' (first four SNVs) were identified in the primary tumor and were validated using PCR and Sanger sequencing on germline and tumor genomic DNA. Those marked as 'Recurrence' (remaining nine SNVs) were identified in the post-treatment secondary tumor and were validated by Illumina sequencing. SNVs in the initial tumor were also identified and validated in the recurrent tumor. |
||||||||||||
|
Jones et al. Genome Biology 2010 11:R82 doi:10.1186/gb-2010-11-8-r82 |
||||||||||||